PSMD2 and non-small cell lung carcinoma: Meanwhile, we constructed three tyrosine kinase inhibitors (TKIs) resistance NSCLC cell lines (PC9OR and HCC827OR: osimertinib resistance; H3122LR: lorlatinib resistance) (Fig. S4A–C), and we found that PSMD2 was highly expressed in 9 types of NSCLC cells (Fig. S4D).